WHO WE ARE

We are advancing a late-stage portfolio of oral small molecule therapeutics with well-characterized mechanisms and distinct features designed to deliver meaningful benefits for people living with neurological and related disorders. We are pursuing both orphan and larger indications for which there are significant medical needs, limited competition, motivated patient communities and compelling scientific rationales suggesting superior clinical benefit.

We collaborate closely with patients, families, caregivers, and healthcare professionals to ensure that real-world experiences, needs, and priorities meaningfully shape our work—from discovery through late-stage development.